Blade Therapeutics benefits from R&D Tax Incentives.

Setting up a biotech subsidiary of a US company in Australia needed Acclime’s guidance and support.

Start reading
  • Client industry:
    Life sciences
  • Services:
    R&D Advisory, company registration, business compliance
  • Country:
    USA

Blade Therapeutics is advancing innovative anti-fibrotic therapies to meet currently unserved patient needs. Several rare/orphan and chronic debilitating conditions manifest with fibrosis, a complex, pathologic process in which healthy cells are replaced by progressively worsening scar tissue (fibrosis). They are committed to developing disease modifying and lifesaving treatments.

Acclime is a great business partner to work with. They offer a one-stop service to cover everything required to manage an Australian subsidiary.

Having worked with Acclime in two R&D incentive applications, I highly recommend Acclime to other biotech companies who are considering setting up a subsidiary in Australia.

Acclime has been instrumental in guiding us successfully through the R&D Tax Incentive program to conduct clinical trials in Australia. Even though I had prior experience in applying this program, I have relied heavily reply on Acclime to keep our company compliant and up to date with local changes.

Shirley Chiang
VP Finance, Blade Therapeutics

Other client stories.

Not sure where to begin?

Get a free 30-minute consultation on starting and operating your company in Australia.

Blair Lucas, Acclime Partner

Schedule a consultation

+61 3 9419 7607

We are open: Monday – Friday
9:00 am to 5.00 pm (UTC+10)

Email us

Services

Company

Solutions

Resources

© Acclime Australia | Privacy policy

Liability limited by a scheme approved under Professional Standards Legislation.